Results 91 to 100 of about 54,679 (264)

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Analysis of interstitial lung disease in pharmacovigilance databases: Coding challenges and interpretation biases—An update

British Journal of Clinical Pharmacology, EarlyView.
Aim Clinically, interstitial lung disease (ILD) is a heterogeneous group of respiratory disorders. Due to their low incidence, pharmacovigilance database analysis is useful to detect them. Precise diagnosis is challenging as well as coding in these databases. Query criteria are among the key elements for a good signal detection.
Romane Freppel, Adeline Benis, Philippe Bonniaud, Jean‐Luc Faillie, Aurélie Grandvuillemin   +4 more
wiley   +1 more source

Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040.

Annals of Oncology
BACKGROUND Nivolumab plus ipilimumab demonstrated promising clinical activity and durable responses in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC) in the CheckMate 040 study at 30.7-month median follow-up.
I. Melero, T. Yau, Y. Kang, T-Y. Kim, A. Santoro, B. Sangro, M. Kudo, Ming-Mo Hou, A. Matilla, F. Tovoli, J. Knox, A.R. He, B. El-Rayes, M. Acosta-Rivera, H. Lim, S. Soleymani, J. Yao, J. Neely, M. Tschaika, C. Hsu, A. El-Khoueiry   +20 more
semanticscholar   +1 more source

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source

Herpes Encephalitis: A Mortal Complication in a Patient Treated with Immunosuppressive Drugs because of Immune-Related Adverse Events after Ipilimumab Treatment

Case Reports in Oncology, 2017
Until a few years ago, metastatic melanoma had a poor prognosis with limited treatment options. These therapeutics options and thereby median survival have increased obviously over 5 years with the arrival of immunotherapeutic drugs like ipilimumab ...
Lieke van Montfort, Caroline M. Loos, Monique Anten, Rob L.H. Jansen   +3 more
doaj   +1 more source

Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial.

European Journal of Cancer
BACKGROUND We report 5-year efficacy and safety outcomes from CheckMate 9LA in patients with metastatic non-small cell lung cancer (mNSCLC) and exploratory analyses in key patient subgroups.
M. Reck, T. Ciuleanu, M. Schenker, S. Bordenave, M. Cobo, Ó. Juan-Vidal, N. Reinmuth, E. Richardet, E. Felip, J. Menezes, Ying Cheng, H. Mizutani, B. Żurawski, A. Alexandru, D. Carbone, Shun Lu, T. John, T. Aoyama, D. Grootendorst, N. Hu, Laura J. Eccles, L. Paz-Ares   +21 more
semanticscholar   +1 more source

Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer

International Journal of Cancer, EarlyView.
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg, Cathrine L. Lorentzen, Marie C. W. Westergaard, Trine Z. Iversen, Troels H. Borch, Marco Donia, Sigrid M. Mannering, Stine E. W. Banke, Özcan Met, Inge Marie Svane   +9 more
wiley   +1 more source

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

Journal for ImmunoTherapy of Cancer, 2018
Background Nivolumab plus ipilimumab improves overall survival and is associated with less toxicity compared with sunitinib in the first-line setting of advanced renal-cell carcinoma (RCC).
Bin Wu, Qiang Zhang, Jie Sun
doaj   +1 more source

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

Journal for ImmunoTherapy of Cancer
Background In CheckMate 9LA, nivolumab plus ipilimumab with chemotherapy prolonged overall survival (OS) versus chemotherapy regardless of tumor PD-L1 expression or histology.
David P. Carbone, T. Ciuleanu, M. Schenker, M. Cobo, S. Bordenave, Ó. Juan-Vidal, J. Menezes, N. Reinmuth, E. Richardet, Ying Cheng, H. Mizutani, E. Felip, B. Żurawski, A. Alexandru, L. Paz-Ares, Shun Lu, Thomas John, Xiaoqing Zhang, Javed Mahmood, N. Hu, Tuli De, I. Santi, J. Penrod, Yong Yuan, Adam Lee, Martin Reck   +25 more
semanticscholar   +1 more source

Real‐World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond

International Journal of Cancer, EarlyView.
Progression after anti‐PD‐1‐based therapy is a predominant scenario in metastatic melanoma. However, real‐world data informing treatment of metastatic melanoma in later lines remains scarce. This retrospective nationwide, population‐based cohort study shows in a real‐world setting that nivolumab plus ipilimumab can induce durable responses beyond the ...
Yago Garitaonaindia, Søren Kjær Petersen, Louise M. Guldbrandt, Troels H. Borch, Christina H. Ruhlmann, Rasmus Blechingberg Friis, Adam A. Luczak, Lars Bastholt, Henrik Schmidt, Inge Marie Svane, Eva Ellebaek, Marco Donia   +11 more
wiley   +1 more source